{"id":"W4412428663","doi":"10.1001/jamanetworkopen.2025.18440","title":"Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non–Small Cell Lung Cancer","year":2025,"lang":"en","type":"article","venue":"JAMA Network Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"Alberta Cancer Foundation","funders":"AstraZeneca","keywords":"Durvalumab; Medicine; Internal medicine; Clinical endpoint; Oncology; Lung cancer; Population; Randomized controlled trial; Chemoradiotherapy; Cancer; Immunotherapy; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001041439,0.0005461721,0.001273706,0.000234972,0.0002270401,0.0005569105,0.0005298624,0.0005108779,0.002916567],"category_scores_gemma":[0.0007292537,0.0002576316,0.0006628424,0.0002562922,0.00048614,0.0006246275,0.000274041,0.001387957,0.0003855152],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006374883,"about_ca_system_score_gemma":0.0007817206,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005884245,"about_ca_topic_score_gemma":0.003962803,"domain_scores_codex":[0.99963,0.000166249,0.00003611866,0.00005679392,0.00004994311,0.00006086925],"domain_scores_gemma":[0.9995949,0.00008121526,0.0001396545,0.0000254331,0.00002177172,0.0001370747],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.8540138,0.01178712,0.01114716,0.001199601,0.002430538,0.0001206464,0.0000847796,0.0008916453,0.01022961,0.0002446322,0.002743138,0.1051073],"study_design_scores_gemma":[0.693661,0.2665758,0.02291963,0.0001289415,0.002432263,0.0002559924,0.00006780311,0.001471513,0.004825895,0.0003255906,0.007303561,0.0000320078],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9878629,0.006665455,0.0003207866,0.0004349609,0.0002664222,0.001378226,0.0006065491,0.00004561055,0.002419065],"genre_scores_gemma":[0.994538,0.001967016,0.0005438548,0.0003559995,0.0001805939,0.0006943308,0.0004412924,0.000006643889,0.001272393],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002916567,"threshold_uncertainty_score":0.009756923,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02943612872246778,"score_gpt":0.3219153829988494,"score_spread":0.2924792542763816,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}